- Glecaprevir-pibrentasvir (GLE/PIB; Mavyret) is similarly safe and effective for clearing HCV in patients aged ≥65 years and their younger counterparts.
Why this matters
- Older age is associated with a greater prevalence of advanced fibrosis and more rapid disease progression, yet elderly patients remain underrepresented in clinical trials.
- Pooled data for 2369 treatment-naive and -experienced patients with HCV genotypes 1-6 receiving 8, 12, or 16 weeks of GLE/PIB across 9 phase 2/3 clinical trials.
- Trials included MAGELLAN-1; SURVEYOR-I, -II; ENDURANCE-1, -2, -3, -4; and EXPEDITION-1, -4.
- Efficacy endpoint: sustained virologic response at 12 weeks posttreatment (SVR12).
- Funding: AbbVie funded the trials and provided medical writing support.
- 324 patients (14%) were aged ≥65 years; most had HCV-1 (42%) or HCV-2 (34%) and were white (68%), treatment-naive (60%), and noncirrhotic (80%).
- Compliance rates were similar vs younger patients (88% vs 90%).
- SVR12 rates were comparably high for patients aged ≥65 years and their younger counterparts (97.9% [95% CI, 96.3%-99.4%] vs 97.3% [95% CI, 96.6%-98.0%], P=.555).
- Of 7 non-SVR12 elderly patients, 3 stopped treatment, 2 had virologic failure, and 2 were lost to follow-up.
- Adverse events leading to discontinuation were rare in both age groups (
- Post-hoc analysis.